A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Inclusion Criteria: * Subject has agreed to participate by providing written informed consent. * Subject will be eligible to participate if one of the following criteria is met: * Subject has completed the 28-week double-blind phase of study D1050238 * Subject has experienced a protocol-defined relapse event during the double- blind phase in study D1050238 * Subject is participating in the open-label or double-blind phase of study D1050238 if/when study D1050238 is terminated by the sponsor. * Subject has completed all required assessments on the final study visit (Study Visit Number 42) in study D1050238. * Subject is judged by the Investigator to be suitable for participation in a 12-week clinical trial involving open-label lurasidone treatment and is able to comply with the protocol in the opinion of the Investigator. Exclusion Criteria: * Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property. * Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS at the extension baseline visit (Study Visit Number 42 in study D1050238). Subjects who answer "yes" to this question must be referred by the Investigator for appropriate follow-up evaluation and treatment. * Subject tests positive for drugs of abuse or is suspected of current alcohol abuse at the extension baseline visit (Study Visit Number 42 in study D1050238). In the event a subject tests positive for cannabinoids, the Investigator will evaluate the subject's ability to abstain from cannabis during the study.